| 3.28 0.03 (0.92%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.31 | 1-year : | 4.78 |
| Resists | First : | 3.69 | Second : | 4.09 |
| Pivot price | 3.35  |
|||
| Supports | First : | 3.02 | Second : | 2.52 |
| MAs | MA(5) : | 3.18  |
MA(20) : | 3.45 |
| MA(100) : | 4.15 |
MA(250) : | 3.96 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 23.2 |
D(3) : | 15.1 |
| RSI | RSI(14): 37.6 |
|||
| 52-week | High : | 5.8 | Low : | 2.42 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ETON ] has closed above bottom band by 38.6%. Bollinger Bands are 15.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.47 - 3.48 | 3.48 - 3.5 |
| Low: | 3.22 - 3.23 | 3.23 - 3.25 |
| Close: | 3.26 - 3.28 | 3.28 - 3.31 |
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Thu, 18 Apr 2024
Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Canada Shine On
Thu, 18 Apr 2024
Eton Pharmaceuticals cancels stock and warrant sale By Investing.com - Investing.com
Fri, 22 Mar 2024
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria - GlobeNewswire
Thu, 14 Mar 2024
Eton Pharmaceuticals Inc (ETON) Reports Robust Sales Growth and Pipeline Progress in Q4 and ... - Yahoo Finance
Thu, 14 Mar 2024
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewswire
Thu, 14 Mar 2024
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 26 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 12.9 (%) |
| Held by Institutions | 27.9 (%) |
| Shares Short | 220 (K) |
| Shares Short P.Month | 227 (K) |
| EPS | -0.04 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.6 |
| Profit Margin | -3 % |
| Operating Margin | -27.3 % |
| Return on Assets (ttm) | -2.7 % |
| Return on Equity (ttm) | -6.6 % |
| Qtrly Rev. Growth | -13.9 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.23 |
| EBITDA (p.s.) | -0.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 7 (M) |
| Levered Free Cash Flow | 6 (M) |
| PE Ratio | -82 |
| PEG Ratio | 0 |
| Price to Book value | 5.46 |
| Price to Sales | 2.66 |
| Price to Cash Flow | 12.35 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|